Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
2633.HK
Strong BuyFLAGJacobson Pharma Corporation Limited · Healthcare · Hong Kong · $267M · Avg Vol: $32K/d
Jacobson Pharma makes generic drugs in Hong Kong and screens very cheap (V89) with modest quality, but momentum is weak (M44) and generic pricing in its core market is competitive. Nothing adverse is known on accounting, solvency or governance, and there is no supportive filings evidence. The default applies.
COMPANY DESCRIPTION
Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the research, development, production, sale, and distribution of medicine and drugs in Hong Kong, Mainland China, Macau, Singapore, and internationally. It operates in two segments, Generic Drugs and Branded Healthcare.
FINANCIAL SUMMARY (HKD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.3B | 1.5B | 1.6B | -0.4% | 1.6B | 1.6B | 1.7B | 3.3% |
| EPS (HKD) | 0.09 | 0.13 | 0.14 | 0.15 | 17.8% | 0.15 | 0.16 | 0.17 | 4.4% |
| Shares | 1.9B | 1.9B | 2.0B | 2.0B | +4.1% | 2.0B | — | — | — |
| Debt | 1.4B | 1.6B | 749.4M | 773.2M | -18.1% | 911.0M | — | — | — |
| Equity | 2.5B | 2.7B | 2.4B | 2.5B | -0.5% | — | — | — | — |
| Op CF | 406.9M | 630.1M | 484.4M | 526.8M | 9.0% | 328.4M | — | — | — |
| Inv CF | -49.9M | -135.0M | 43.3M | -297.8M | — | — | — | — | — |
| Fin CF | -357.9M | -36.6M | -1.1B | -131.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 2633.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 2633.HK | Jacobson Pharma Corporation Limited(you) | $267M | 94 | Strong Buy |
| 3839.HK | CPBIO Holding Company Limited | $270M | 96 | Strong Buy |
| 2161.HK | JBM (Healthcare) Limited | $192M | 89 | Strong Buy |
| 2348.HK | Dawnrays Pharmaceutical (Holdings) Limited | $192M | 99 | Strong Buy |
| 8049.HK | Jilin Province Huinan Changlong Bio-pharmacy Company Limited | $168M | 100 | Strong Buy |
| 3613.HK | Beijing Tong Ren Tang Chinese Medicine Company Limited | $694M | 93 | Strong Buy |
| 0950.HK | Lee's Pharmaceutical Holdings Limited | $101M | 76 | Buy |
| 2005.HK | SSY Group Limited | $994M | 82 | Strong Buy |
| 0570.HK | China Traditional Chinese Medicine Holdings Co. Limited | $893M | 69 | Buy |
| 3320.HK | China Resources Pharmaceutical Group Limited | $3.7B | 93 | Strong Buy |
Peer medians: ROE 6.3% · P/E 11.5x · Gross margin 38.1%